Kymera Therapeutics (NASDAQ:KYMR) Director Sells $556,594.23 in Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Bruce Booth sold 6,101 shares of the company’s stock in a transaction dated Thursday, December 11th. The stock was sold at an average price of $91.23, for a total transaction of $556,594.23. Following the completion of the sale, the director owned 685,501 shares in the company, valued at $62,538,256.23. This represents a 0.88% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Bruce Booth also recently made the following trade(s):

• On Friday, December 12th, Bruce Booth sold 678 shares of Kymera Therapeutics stock. The shares were sold at an average price of $91.04, for a total value of $61,725.12.
• On Wednesday, December 10th, Bruce Booth sold 229,809 shares of Kymera Therapeutics stock. The stock was sold at an average price of $91.73, for a total value of $21,080,379.57.

Kymera Therapeutics Stock Up 2.1%

Shares of Kymera Therapeutics stock opened at $89.68 on Monday. Kymera Therapeutics, Inc. has a 52 week low of $19.44 and a 52 week high of $103.00. The business has a 50 day moving average price of $64.77 and a 200-day moving average price of $52.18. The company has a market cap of $6.45 billion, a PE ratio of -24.98 and a beta of 2.28.

Kymera Therapeutics (NASDAQ:KYMR) last announced its earnings results on Tuesday, November 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.19). The company had revenue of $2.76 million for the quarter, compared to analysts’ expectations of $23.15 million. Kymera Therapeutics had a negative net margin of 674.81% and a negative return on equity of 32.92%. As a group, research analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of KYMR. Siren L.L.C. lifted its holdings in Kymera Therapeutics by 9.1% during the first quarter. Siren L.L.C. now owns 3,240,313 shares of the company’s stock valued at $88,687,000 after purchasing an additional 270,580 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH raised its position in shares of Kymera Therapeutics by 26.3% in the second quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 107,438 shares of the company’s stock valued at $4,689,000 after purchasing an additional 22,392 shares during the period. Rhumbline Advisers lifted its stake in shares of Kymera Therapeutics by 9.0% during the 1st quarter. Rhumbline Advisers now owns 69,928 shares of the company’s stock valued at $1,914,000 after buying an additional 5,771 shares in the last quarter. Atika Capital Management LLC bought a new position in Kymera Therapeutics in the 2nd quarter worth approximately $6,398,000. Finally, Farther Finance Advisors LLC boosted its holdings in Kymera Therapeutics by 642.9% in the 2nd quarter. Farther Finance Advisors LLC now owns 624 shares of the company’s stock worth $27,000 after buying an additional 540 shares during the period.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. Royal Bank Of Canada started coverage on shares of Kymera Therapeutics in a report on Tuesday, September 16th. They issued an “outperform” rating and a $70.00 target price for the company. Morgan Stanley increased their price objective on shares of Kymera Therapeutics from $73.00 to $127.00 and gave the company an “overweight” rating in a research note on Tuesday, December 9th. Stifel Nicolaus set a $114.00 target price on Kymera Therapeutics in a research note on Monday, December 8th. UBS Group raised Kymera Therapeutics to a “strong-buy” rating in a report on Thursday, December 4th. Finally, Barclays lifted their price target on Kymera Therapeutics from $70.00 to $119.00 and gave the stock an “overweight” rating in a report on Tuesday, December 9th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $112.80.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.